目的 探讨肺力咳胶囊联合依替米星治疗慢性支气管炎急性加重期的有效性与安全性。方法 选取2015年7月—2017年7月在郑州市第九人民医院治疗的慢性支气管炎急性加重期患者176例，随机分为对照组（88例）和治疗组（88例）。对照组患者静脉滴注硫酸依替米星注射液，100 mg加入5%葡萄糖注射液250 mL，2次/d；治疗组患者在对照组基础上口服肺力咳胶囊，3粒/次，3次/d。两组患者均连续治疗2周。观察两组患者临床疗效，同时比较治疗前后两组患者临床症状消失时间、SF-36评分和症状积分、血清炎症因子、肺表面活性蛋白A水平和不良反应情况。结果 治疗后，对照组临床有效率为85.23%，显著低于治疗组的95.45%，两组比较差异具有统计学意义（P<0.05）。治疗后，治疗组患者哮鸣音、咳痰等症状消失时间均显著早于对照组（P<0.05）。治疗后，两组患者SF-36评分显著升高（P<0.05），症状积分显著降低（P<0.05），且治疗组患者SF-36评分和症状积分明显优于对照组（P<0.05）。治疗后，两组患者血清肿瘤坏死因子-α（TNF-α）和IL-6水平显著降低（P<0.05），肺表面活性蛋白A（SP-A）水平显著升高（P<0.05），且治疗组患者血清炎症因子和SP-A明显优于对照组患者（P<0.05）。治疗期间，治疗组患者不良反应发生率为2.27%，显著低于对照组的11.36%，两组比较差异具有统计学意义（P<0.05）。结论 肺力咳胶囊联合依替米星治疗慢性支气管炎急性加重期疗效显著，安全性高，具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy and safety of Feilike Capsules combined with etimicin in treatment of acute exacerbation of chronic bronchitis. Methods Patients (176 cases) with acute exacerbation of chronic bronchitis in Ninth People's Hospital of Zhengzhou from July 2015 to July 2017 were randomly divided into control (88 cases) and treatment (88 cases) groups. Patients in the control group were iv administered with Etimicin Sulfate Injection, 100 mg added into 5% glucose injection 250 mL, twice daily. Patients in the treatment group were po administered with Feilike Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy was evaluated, and the clinical symptoms disappearance time, SF-36 scores, symptom scores, serum inflammatory factors levels, lung surfactant protein A levels and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 85.23%, which was significantly lower than 95.45% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the disappearance time of wheezing rale and expectoration in treatment group was significantly earlier than that in the control group (P<0.05). After treatment, the SF-36 scores in two groups were significantly increased (P<0.05), but symptom scores were significantly decreased (P<0.05), and these scores in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the TNF-α and IL-6 levels in two groups were significantly decreased (P<0.05), lung surfactant protein A levels were significantly increased (P<0.05), and serum inflammatory factors levels, lung surfactant protein A levels in the treatment group were significantly better than those in the control group (P<0.05). During the treatment, the adverse reactions rate in the treatment group was 2.27%, which was significantly lower than 11.36% in the control group, with significant difference between two groups (P<0.05). Conclusion Feilike Capsules combined with etimicin has significant curative effect on acute exacerbation of chronic bronchitis with high safety, which has a certain clinical application value.